A new software model is the first to provide a rolling prediction about the next 24 hours after each blood glucose measurement is taken in hospitalized patients with diabetes. Through machine learning, the model integrated dozens of clinical predictors via links to electronic hospital records. A new study could move hospitals a step closer...
People with type 2 diabetes should be considered in remission after sustaining normal blood sugar levels for three months or more, according to a new consensus statement from the Endocrine Society, the European Association for the Study of Diabetes, Diabetes UK and the American Diabetes Association published in The Journal of Clinical Endocrinology & Metabolism. About 10%...
Americans diagnosed with hypothyroidism and their clinical providers now have access to greater dosage flexibility within levothyroxine therapy, with three new dosage strengths of levothyroxine sodium oral solution now available to treat hypothyroidism. IBSA Pharma markets the drug as Tirosint®-SOL. The unique new dosing options – 37.5, 44 and 62.5 micrograms – are a first...
HealthPartners Institute’s International Diabetes Center (IDC) recently developed and piloted a process for incorporating patients’ continuous glucose monitoring (CGM) data directly into the electronic health record (EHR), improving clinician access to glucose information. During a presentation at the American Diabetes Association’s 81st Scientific Sessions, IDC medical director Amy Criego, MD, described this process for integrating...
Although more than half of Americans over 65 meet criteria for prediabetes, most of them will not progress to developing diabetes. While conflicting messages abound regarding prediabetes, the Endocrine Society recommends an oral glucose tolerance test for those older patients at greatest risk for developing diabetes. The scientist who helped popularize the term prediabetes now...
The U.S. Food and Drug Administration this week cleared Abbott’s FreeStyle® Libre 2 iOS application for use with compatible iPhones, to pair with its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Approved for adults and children (4 and older) with diabetes, the new app enables users to get glucose readings directly on their...
[Editor’s Note: This post has been updated to include comments from Rita Kalyani, MD.] When the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product last month, many were hailing this as a breakthrough in treating diabetes. The impacts could be immediately felt by people rationing their insulin due to cost as...
A once-weekly injectable suspension has been approved in the U.S. for the treatment of type 2 diabetes. Marketed by AstraZeneca as BYDUREON BCise (exenatide extended-release), it has been shown to to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and...
Although more than half of Americans over 65 meet criteria for prediabetes, most of them will not progress to developing diabetes. While conflicting messages abound regarding prediabetes, the Endocrine Society recommends an oral glucose tolerance test for those older patients at greatest risk for developing diabetes. The scientist who helped popularize the term prediabetes now...
The U.S. Food and Drug Administration this week cleared Abbott’s FreeStyle® Libre 2 iOS application for use with compatible iPhones, to pair with its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Approved for adults and children (4 and older) with diabetes, the new app enables users to get glucose readings directly on their...
